Gilead Sciences | GILD - Des Atouts





Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
ALKERMES USD 4.39B 135.05M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Amgen USD 95.64B 3.14B 2026-06
Biogen USD 32.09B 2.6B 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Coherus Biosciences USD 191.18M 74.84M 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Gilead Sciences USD 49.36B 6.92B 2026-06
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
Glaxosmithkline GBP 62.87B 19.47B 2026-03
Incyte USD 7.87B 533.53M 2026-06
J&J USD 201.06B 167M 2026-06
Merck USD 129.8B 1.12B 2026-06
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Pfizer USD 201.13B 6.49B 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 129.06B 1.04B 2026-06
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
United Therapeutics USD 7.22B 505.9M 2026-06
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06